Pipeline

Seven programs. One platform.

Each program applies the metabolic state thesis to a disease where bioenergetic dysfunction is a demonstrated upstream driver. Every program links to a full scientific brief with published evidence and mechanistic rationale.

SNV-401NeurologyLead Program

Drug-Resistant Epilepsy

Developing an oral medicine designed to achieve sustained therapeutic ketosis without dietary restriction. The ketogenic diet achieves 55% seizure reduction in drug-resistant epilepsy (Cochrane 2020). No pharmaceutical equivalent exists.

View scientific brief →
SNV-201NeurologyDiscovery

Alzheimer’s Disease & Neurodegeneration

Restoring brain bioenergetic capacity via pharmaceutical-grade ketone delivery. Brain glucose hypometabolism precedes Alzheimer’s pathology by decades and may gate the efficacy of amyloid-clearing drugs.

View scientific brief →
SNV-801CardiologyDiscovery

Heart Failure

Building on the SGLT2 inhibitor ketone signal. Six completed RCTs demonstrate direct hemodynamic benefit: +2.0 L/min cardiac output, 18% NT-proBNP reduction. A pharmaceutical-grade metabolic inotrope.

View scientific brief →
SNV-601OncologyDiscovery

Immuno-Oncology

Metabolic rescue of exhausted T-cells in the tumor microenvironment. Published data shows higher metabolic reserve correlates with 28–51% better IO survival. Over 70% tumor eradication in IO-resistant preclinical models.

View scientific brief →
SNV-301PsychiatryDiscovery

Serious Mental Illness

Addressing the metabolic dimensions of psychiatric illness. Published clinical data: 46% PANSS reduction in treatment-resistant schizophrenia, with 100% of participants showing improvement.

View scientific brief →
SNV-701ImmunologyPlatform

Autoimmune Disease

Multi-node immune modulation through metabolic state control. Published clinical remission in treatment-resistant ulcerative colitis. Seven validated anti-inflammatory pathways engaged simultaneously.

View scientific brief →
SNV-901Infectious DiseasePlatform

Infectious Disease & AMR

Host-directed therapy for antimicrobial resistance. Published data on bacterial membrane permeabilization, immune cell activation, and complete malaria protection in preclinical models.

View scientific brief →

For partnership inquiries, scientific collaboration, and investment discussions.

Contact UsView all research →